61
Maria Grazia Pau, Alphonsus G C M UytdeHaag: Production of vaccines. Crucell Holland, TraskBritt, November 16, 2010: US07833788 (2 worldwide citation)

Means and methods are provided for the production of mammalian viruses comprising: infecting a culture of immortalized human cells with the virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus-containing medium ...


62
Erich Hoffmann, Aleksandr S Lipatov, Richard J Webby, Elena A Govorkova, Robert G Webster: Modified influenza virus for monitoring and improving vaccine efficiency. St Jude Children s Research Hospital, Fish & Richardson P C, January 18, 2011: US07871626 (2 worldwide citation)

The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by alt ...


63
Jules Maarten Minke, Kemal Karaca, Jiansheng Yao: Canine influenza vaccines. Mevial, Judy Jarecki Black, Mevial, Thomas Kowalski Esq, September 16, 2008: US07425336 (2 worldwide citation)

The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens w ...


64
Influenza vaccines. Sandoz, January 18, 1978: GB1498261-A (2 worldwide citation)

1498261 Influenza vaccines SANDOZ Ltd 13 Jan 1975 [14 Jan 1974] 1290/75 Heading A5B The haemagglutinin and neuramuridase components are isolated from influenza virus by treating the virus in an aqueous medium with a cationic detergent to selectively solubilise such components, and separating the res ...


65
Adamowicz Philippe, Muller Ludwig: Procede pour obtenir des sous-unites virales enrobees de lipide, notamment des antigenes utilises dans des vaccins, produit ainsi obtenu et applications, Process for obtaining lipid envelope virus subunits, notably antigens for use as vaccines, the products obtained and their applications. Institut Pasteur, GOWLING LAFLEUR HENDERSON, December 20, 1983: CA1158978 (2 worldwide citation)

ABSTRACT OF DISCLOSURE The invention relates to a process for producing virus subunits with lipid envelopes. The process consists using a neutral or basic pH: (1)in dissolving a lower halogenated hydrocarbon, at a concentration equivalent to or approximating its limit of solubility, in an aqueous vi ...


66
Lu bin, Hong Jin: Multi-plasmid system for the production of influenza virus. Medimmune, Lu bin, Hong Jin, HOLMES SON Michelle, April 26, 2007: WO/2007/048089 (2 worldwide citation)

Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing ...


67
Rappuoli Rino, O Hagan Derek, Del, Giudice Giuseppe: Adjuvanted influenza vaccines including cytokine-inducing agents. Novartis Vaccines And Diagnostics, Rappuoli Rino, O Hagan Derek, Del, Giudice Giuseppe, MARSHALL Cameron John, May 10, 2007: WO/2007/052056 (2 worldwide citation)

While oil-in-water emulsions are excellent adjuvants for influenza vaccines, their efficacy can be improved by additionally including other immunostimulating agent(s) to improve cytokine responses, such as ϝ-interferon response. Thus a vaccine comprises: (i) an influenza virus antigen; (ii) a ...


68
Jules Maarten Minke, Kemal Karaca, Jiansheng Yao: Canine influenza vaccines. Merial, Judy Jarecki Black, Merial, Thomas Kowalski, June 10, 2008: US07384642 (2 worldwide citation)

The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens w ...


69
O Hagan Derek: Changing th1/th2 balance in split influenza vaccines with adjuvants. Novartis Vaccines And Diagnostics, O Hagan Derek, MARSHALL Cameron John, May 10, 2007: WO/2007/052059 (2 worldwide citation)

The invention seeks to avoid components in split vaccines that could cause an excessive Th2 response. Thus the invention provides an immunogenic composition comprising a split influenza virus antigen and a Th1 adjuvant, wherein the antigen is preferably prepared from a virus grown in cell culture (e ...


70
Scheffczik Hanno: Storage of influenza vaccines without refrigeration. Novartis Vaccines And Diagnostics & Co Kg, Scheffczik Hanno, MARSHALL Cameron John, October 4, 2007: WO/2007/110776 (2 worldwide citation)

Antigens from individual influenza virus strains are not refrigerated before being combined to make multivalent influenza virus vaccines. Moreover, influenza vaccines are not refrigerated between packaging and administration. Thus the need for refrigeration is minimized, and the cold-chain does not ...



Click the thumbnails below to visualize the patent trend.